John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.
John F. Lazar, MD
Advertisement
Articles by John F. Lazar, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
QOL, Efficacy, and Cost Considerations Help Drive TKI Treatment Selection in CML
2
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
3
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
4
A Randomized Phase III Study Evaluating Izalontamab Brengitecan (Iza-bren) Versus Physician’s Choice of Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
5